Industry Symposium – Lilly

Advancing Migraine Prevention: What have we learned thus far? - Cristina Tassorelli, Dr Giorgio Lambru & Julio Pascual Gómez

• Monoclonal antibodies: their relevance in current treatment paradigm with emergence of newer therapies?
• Important factors to consider in migraine treatment decision making?
• What have we learned from Switching or Stopping treatments with mAbs in clinical practice?
• Q&A

Plenary 1: Celebration of the Retirement of Professor MD Ferrari

Chair: Jean Schoenen

• How should we treat women with migraine?, Gisela Terwindt
• Advances in the genetics of migraine, Arn van den Maagdenberg
• The exciting migraine brain, Else Tolner
• Neuromodulation for cluster headache, Rolf Fronczek
• Advances in migraine treatment pharmacology, Antoinette Maassen van den Brink
• Panel discussion

Break

Presented Abstract Submission

Early Career Investigators Session

Industry Symposium - AbbVie

Evolving faces of Migraine - Dr Manjit Matharu & Dr Messoud Ashina

• The many faces of migraine
• The shifting paradigm in migraine management
• Individualized therapy
• Questions & answers

Lunch & Posters

Industry Symposium - Pfizer

Parallel Session 1 - PhD/Body of work presentations

Chair: Cristina Tassorelli

Parallel Session 2 - Migraine – out of the mainstream

• Migraine premonitory phase: from the bench, Philip Holland
• Pediatric headache - what’s new?, Prab Prabhakar
• Vestibular migraine, David Moreno-Ajona

Break

Migraine Trust Lecture

The High’s and the Low’s in Headache, Rigmor Jensen

Industry Symposium - Teva Migraine Team

Real-world insights to inform personalised approaches in migraine prevention - Christoph Schankin, Dr Giorgio Lambru & Piero Barbanti

• Welcome and introductions, Piero Barbanti (Chair)
• How do we interpret personalized medicine in migraine, does it matter and is it achievable?
• Real-world insights: a gateway to personalised medicine for migraine prevention, Christoph J Schankin
• When one size does not fit all: what RWE teaches us about migraine prevention in individual patients, Giorgio Lambru
• Questions & answers

Plenary 2 - Modelling Migraine

Chairs: Shazia Afridi and Philip R. Holland

• Mechanisms and interactions of migraine inducing messenger molecules in animal models, Sarah Louise Tangsgaard Christensen
• Human Cells and Networks of Pain, William Renthal
• Going beyond the canonical CGRP receptor: promise and pitfalls, Professor Deborah Hay

Break

Parallel Session 3 - Novel Therapeutic Targets in Migraine

• Delta opioid, Amynah Pradhan Adenosine receptors, Andy Charles
• Sex differences in preclinical migraine models, Greg Dussor

Parallel Session 4 - Other Headache Types

• Post-COVID-19 Headache, Tesha Monteith
• Idiopathic Intracranial Hypertension & Headache, Dr Alexandra Sinclair
• Hypnic Headache, Mario Peres

Industry Symposium – Novartis

Respecting time in migraine management

Chair: Patricia Pozo-Rosich

• Assessing the evidence for CGRP mAbs: What has time told us?, Dagny Holle-Lee
• Changing times in migraine management: How do guidelines help?, Simona Sacco
• Is it time to APPRAISE our approach to migraine prophylaxis? Patricia Pozo-Rosich
• The importance of time in patient management Teshamae Monteith
• Closing remarks Patricia Pozo-Rosich

Lunch & Posters

Industry Symposium - Pfizer

Oral Communications

Chair: Lars Edvinsson

Parallel Session 5 - Cluster headache

• Cluster headache and PACAP, Lanfranco Pellesi
• Genetics of cluster headache, Aster Harder
• Update on therapy of cluster headache, Diana Wei

Parallel Session 6

Session Chair: Gisela Terwindt

• "Do good and talk about it. an editor's view of social media", Arne May
• Gepants: from clinical trials to clinical practice Stewart Tepper
• Evolving views on the treatment of chronic migraine with medication overuse, Todd J. Schwedt

Oral Communications

Industry Symposium – Lundbeck

Chronic Migraine: Design and Persistence in Therapy - Peter Goadsby, Astrid Gendolla & Stewart Tepper

• The typical migraine patient pathway and the important of long-term follow-up of patients with chronic migraine
• Sequential goal setting (SGS) and the potential benefits of this approach in the management of chronic migraine
• The role SGS could play within the current chronic migraine environment, which includes new preventive therapies and a focus on patient-centered care

Plenary Session

Headache Treatment Controversies

• Update on Migraine Aura phenotyping, Michele Viana
• Psychological aspects of headache: from neurobiology to treatment, Sara Bottiroli
• Post-traumatic headache, Henrik Schytz

Nappi Cluster Lecture Session Roberto de Icco

Closing